These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 10693152

  • 21. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J, Koszycki D.
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [Abstract] [Full Text] [Related]

  • 22. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder.
    Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC.
    Neuropsychopharmacology; 1996 Jul; 15(1):7-15. PubMed ID: 8797187
    [Abstract] [Full Text] [Related]

  • 23. Corticotropin releasing hormone: relevance to normal physiology and to the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency.
    Gold PW, Kling MA, Khan I, Calabrese JR, Kalogeras K, Post RM, Avgerinos PC, Loriaux DL, Chrousos GP.
    Adv Biochem Psychopharmacol; 1987 Jul; 43():183-200. PubMed ID: 3035886
    [Abstract] [Full Text] [Related]

  • 24. Stress responsive neurohormones in depression and anxiety.
    Ströhle A, Holsboer F.
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
    [Abstract] [Full Text] [Related]

  • 25. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL, Liberzon I, Young EA, Khan S.
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [Abstract] [Full Text] [Related]

  • 26. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects.
    Flint AJ, Koszycki D, Bradwejn J, Vaccarino FJ.
    Psychoneuroendocrinology; 2000 Aug; 25(6):633-47. PubMed ID: 10840174
    [Abstract] [Full Text] [Related]

  • 27. Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder.
    Belgorodsky A, Knyazhansky L, Loewenthal U, Arbelle J, Cohen H, Benjamin J.
    Depress Anxiety; 2005 Aug; 21(3):143-8. PubMed ID: 16001448
    [Abstract] [Full Text] [Related]

  • 28. Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder.
    Erhardt A, Ising M, Unschuld PG, Kern N, Lucae S, Pütz B, Uhr M, Binder EB, Holsboer F, Keck ME.
    Neuropsychopharmacology; 2006 Nov; 31(11):2515-22. PubMed ID: 16841071
    [Abstract] [Full Text] [Related]

  • 29. Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol.
    Abelson JL, Curtis GC.
    Arch Gen Psychiatry; 1996 Apr; 53(4):323-31. PubMed ID: 8634010
    [Abstract] [Full Text] [Related]

  • 30. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic.
    Kellner M, Herzog L, Yassouridis A, Holsboer F, Wiedemann K.
    Am J Psychiatry; 1995 Sep; 152(9):1365-7. PubMed ID: 7653695
    [Abstract] [Full Text] [Related]

  • 31. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
    Ströhle A.
    Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
    [Abstract] [Full Text] [Related]

  • 32. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
    Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K.
    Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
    [Abstract] [Full Text] [Related]

  • 33. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
    Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, Kellner M.
    Neuropsychopharmacology; 2007 Jan; 32(1):232-8. PubMed ID: 17035932
    [Abstract] [Full Text] [Related]

  • 34. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder.
    Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A.
    Horm Metab Res Suppl; 1987 Jan; 16():80-8. PubMed ID: 2832300
    [Abstract] [Full Text] [Related]

  • 35. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD, Slate SO, Geraci M, Uhde TW.
    Anxiety; 1987 Jan; 1(6):258-67. PubMed ID: 9160584
    [Abstract] [Full Text] [Related]

  • 36. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Jan; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

  • 37. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
    Plag J, Gaudlitz K, Zschucke E, Yassouridis A, Pyrkosch L, Wittmann A, Holsboer F, Ströhle A.
    Curr Pharm Des; 2012 Jan; 18(35):5619-26. PubMed ID: 22632477
    [Abstract] [Full Text] [Related]

  • 38. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J, Koszycki D, Meterissian G.
    Can J Psychiatry; 1990 Feb; 35(1):83-5. PubMed ID: 2180549
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
    Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la Motte S, Engel R, Kucher K, Rupprecht R.
    Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
    [Abstract] [Full Text] [Related]

  • 40. Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia.
    Siegmund A, Köster L, Meves AM, Plag J, Stoy M, Ströhle A.
    J Psychiatr Res; 2011 Mar; 45(3):339-46. PubMed ID: 20673917
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.